Status:
COMPLETED
The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males
Lead Sponsor:
Arthrosi Therapeutics
Conditions:
Healthy Volunteers
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
A randomized, double-blind, placebo-controlled, single ascending dose study of AR882 in healthy adult males.
Eligibility Criteria
Inclusion
- Serum uric acid level ≥ 4.5 mg/dL (268 µmol/L)
- Body weight no less than 50 kg and body mass index (BMI) within the range of ≥18 and ≤33 kg/m2
- Must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations or procedures
Exclusion
- Malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin
- History of cardiac abnormalities
- History and/or presence of drug addiction or excessive use of alcohol
Key Trial Info
Start Date :
January 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2019
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT04347005
Start Date
January 22 2019
End Date
July 31 2019
Last Update
November 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nucleus Network Pty, Ltd.
Melbourne, Victoria, Australia, 3004